|
US4515810A
(en)
*
|
1983-10-06 |
1985-05-07 |
American Cyanamid Company |
Composition of matter
|
|
US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5004651A
(en)
*
|
1989-01-24 |
1991-04-02 |
Abbott Laboratories |
Stabilizing system for solid dosage forms
|
|
AU645070B2
(en)
*
|
1990-04-10 |
1994-01-06 |
Nb International Technologies |
Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
US6432994B1
(en)
|
1997-04-28 |
2002-08-13 |
Texas Biotechnology Corporation |
Sulfonamides for treatment of endothelin-mediated disorders
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
US7169410B1
(en)
*
|
1998-05-19 |
2007-01-30 |
Sdg, Inc. |
Targeted liposomal drug delivery system
|
|
AU1624801A
(en)
|
1999-11-19 |
2001-05-30 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists related applications
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
AU2002351412B2
(en)
|
2001-12-21 |
2010-05-20 |
Exelixis Patent Company Llc |
Modulators of LXR
|
|
US6696473B2
(en)
*
|
2001-12-21 |
2004-02-24 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
AU2003248747A1
(en)
|
2002-06-27 |
2004-01-19 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
|
WO2004005289A2
(en)
|
2002-07-02 |
2004-01-15 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its derivatives
|
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7767429B2
(en)
|
2003-03-05 |
2010-08-03 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
EP1628666B1
(en)
*
|
2003-05-14 |
2015-09-23 |
NeuroGenetic Pharmaceuticals, Inc. |
Compouds and uses thereof in modulating amyloid beta
|
|
AU2004251668B2
(en)
*
|
2003-06-03 |
2008-03-20 |
Triad Therapeutics, Inc |
5-membered heterocycle-based p-38 inhibitors
|
|
US7057100B2
(en)
*
|
2003-06-26 |
2006-06-06 |
The J.C. Robinson Seed Co. |
Inbred corn line W23129
|
|
EP1911754B1
(en)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US20050203184A1
(en)
*
|
2003-09-10 |
2005-09-15 |
Petasis Nicos A. |
Benzo lipoxin analogues
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
CA2580584C
(en)
|
2003-09-19 |
2015-07-28 |
Galileo Pharmaceuticals, Inc. |
Use of alpha-tocotrienol for treatment of mitochondrial diseases
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(en)
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
US8519158B2
(en)
*
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
JP2007538103A
(ja)
|
2004-05-20 |
2007-12-27 |
ザ スクリップス リサーチ インスティテュート |
トランスサイレチン安定化
|
|
EP1765332A2
(en)
*
|
2004-06-17 |
2007-03-28 |
Cengent Therapeutics, Inc. |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
|
WO2006017124A2
(en)
*
|
2004-07-09 |
2006-02-16 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
BRPI0513310A
(pt)
|
2004-07-12 |
2008-05-06 |
Idun Pharmaceuticals Inc |
análogos de tetrapeptìdeo
|
|
US20060034978A1
(en)
*
|
2004-08-16 |
2006-02-16 |
Grain Processing Corporation |
Aerosol compositions, devices and methods
|
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
NZ588432A
(en)
|
2004-09-17 |
2012-03-30 |
Whitehead Biomedical Inst |
Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
|
|
ES2401285T3
(es)
|
2004-12-16 |
2013-04-18 |
The Regents Of The University Of California |
Fármacos con el pulmón como diana
|
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
|
CA2621365C
(en)
|
2005-05-23 |
2012-09-04 |
Natural Alternatives International |
Compositions and methods for the sustained release of beta-alanine
|
|
BRPI0609191B8
(pt)
|
2005-06-17 |
2021-05-25 |
Ligand Pharm Inc |
métodos e compostos moduladores de receptor de androgênio
|
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
AU2007225139A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
|
CA2644784A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Jinling Chen |
Formulations of sitaxsentan sodium
|
|
WO2007106537A2
(en)
|
2006-03-13 |
2007-09-20 |
Activx Biosciences, Inc. |
Aminoquinolones as gsk-3 inhibitors
|
|
EP2007373A4
(en)
*
|
2006-03-29 |
2012-12-19 |
Foldrx Pharmaceuticals Inc |
INHIBITION OF ALPHA SYNUCLEINE TOXICITY
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
|
CN101535304A
(zh)
|
2006-09-21 |
2009-09-16 |
埃迪威克斯生物科学公司 |
丝氨酸水解酶抑制剂
|
|
EP2079696A2
(en)
|
2006-10-09 |
2009-07-22 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
EP2223925A1
(en)
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
BRPI0715579A2
(pt)
|
2006-10-19 |
2015-05-26 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica e uso de um composto"
|
|
SI2076268T1
(sl)
|
2006-10-19 |
2013-04-30 |
Genzyme Corpoartion |
Roskovitin za zdravljenje določenih cističnih bolezni
|
|
EP2113500A1
(en)
|
2006-10-31 |
2009-11-04 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
|
WO2008079371A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
|
BRPI0808089A2
(pt)
*
|
2007-02-28 |
2014-07-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
ES2693948T3
(es)
|
2007-03-15 |
2018-12-14 |
Auspex Pharmaceuticals, Inc. |
Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
|
|
MX2010000465A
(es)
*
|
2007-07-12 |
2010-08-30 |
Tragara Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
|
|
CN101855228B
(zh)
*
|
2007-09-11 |
2012-10-24 |
杏林制药株式会社 |
作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
|
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
|
US20110201818A1
(en)
|
2007-09-25 |
2011-08-18 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
EP2205244B1
(en)
|
2007-11-08 |
2013-08-21 |
Ambit Biosciences Corporation |
Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]-phenyl}urea to treat proliferative disease
|
|
CA2706465A1
(en)
|
2007-11-21 |
2009-05-28 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of ssao/vap-1 and uses therefor
|
|
JP5539221B2
(ja)
|
2007-12-21 |
2014-07-02 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）およびその使用
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
PL2947072T3
(pl)
|
2008-03-17 |
2017-05-31 |
Ambit Biosciences Corporation |
1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
|
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
AU2009249600A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Cerenis Therapeutics Holding S.A. |
Niacin and NSAID for combination therapy
|
|
EP2311842A3
(en)
|
2008-06-24 |
2011-07-13 |
Takeda Pharmaceutical Company Limited |
PI3K/M TOR inhibitors
|
|
ES2732453T3
(es)
|
2008-07-01 |
2019-11-22 |
Curemark Llc |
Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
|
|
JP2012514604A
(ja)
|
2009-01-06 |
2012-06-28 |
キュレロン リミテッド ライアビリティ カンパニー |
大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
|
|
CA3050530A1
(en)
|
2009-01-06 |
2010-07-15 |
Galenagen, Llc |
Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
PL2401267T3
(pl)
|
2009-02-27 |
2014-06-30 |
Ambit Biosciences Corp |
Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
|
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス，インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
|
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
|
AU2010228982B2
(en)
|
2009-03-23 |
2015-05-14 |
Ambit Biosciences Corporation |
Methods of treatment using combination therapy
|
|
EP2415767B1
(en)
|
2009-03-27 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
Poly (ADP-ribose) Polymerase (PARP) Inhibitors
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
AU2010229468A1
(en)
|
2009-03-27 |
2011-10-13 |
Vetdc, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
AR076363A1
(es)
|
2009-04-22 |
2011-06-08 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida
|
|
PE20120810A1
(es)
|
2009-04-22 |
2012-07-08 |
Axikin Pharmaceuticals Inc |
Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3
|
|
SG175748A1
(en)
|
2009-04-22 |
2011-12-29 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
|
SMT202000092T1
(it)
|
2009-05-14 |
2020-05-08 |
Ambit Biosciences Corp |
Formulazione essiccata a spruzzo o liofilizzata di ac220
|
|
US8486939B2
(en)
|
2009-07-07 |
2013-07-16 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
ES2655883T5
(es)
|
2009-07-08 |
2022-04-18 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Composiciones farmacéuticas que contienen tiosulfato de sodio
|
|
JP5715625B2
(ja)
|
2009-07-30 |
2015-05-07 |
武田薬品工業株式会社 |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
|
CN102724978A
(zh)
|
2009-08-14 |
2012-10-10 |
塞伦尼斯治疗公司 |
用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途
|
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
|
TW201120037A
(en)
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
|
CA2779736A1
(en)
*
|
2009-11-03 |
2011-05-12 |
Bernard Charles Sherman |
Stable pharmaceutical formulations comprising lubiprostone
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011057214A2
(en)
|
2009-11-09 |
2011-05-12 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
SG181797A1
(en)
|
2009-12-18 |
2012-07-30 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
EP2515654A4
(en)
*
|
2009-12-23 |
2013-04-24 |
Map Pharmaceuticals Inc |
NEW ERGOLINANALOGA
|
|
CA2784799C
(en)
|
2009-12-30 |
2014-06-10 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain dipeptidyl peptidase inhibtors
|
|
WO2011097079A1
(en)
|
2010-02-03 |
2011-08-11 |
Takeda Pharmaceutical Company Limited |
Apoptosis signal-regulating kinase 1 inhibitors
|
|
EP2542542B1
(en)
|
2010-03-02 |
2015-04-22 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
WO2011116161A2
(en)
|
2010-03-17 |
2011-09-22 |
Axikin Pharmaceuticals Inc. |
Arylsulfonamide ccr3 antagonists
|
|
US9408831B2
(en)
|
2010-04-07 |
2016-08-09 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
|
WO2011153197A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
|
CA2801003A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
|
NZ604018A
(en)
|
2010-06-07 |
2015-02-27 |
Novomedix Llc |
Furanyl compounds and the use thereof
|
|
EP2585455B1
(en)
|
2010-06-24 |
2019-08-07 |
The Regents of the University of California |
Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
|
|
US20140200270A1
(en)
|
2013-01-11 |
2014-07-17 |
Summa Health System |
Vitamins c and k for treating polycystic diseases
|
|
MX347927B
(es)
|
2010-07-19 |
2017-05-19 |
Summa Health System |
Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
|
|
WO2012030910A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
WO2012030914A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Boisciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
AU2011296024B2
(en)
|
2010-09-01 |
2015-05-28 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
EP2611502A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
EP2611812A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
EP2611792B1
(en)
|
2010-09-01 |
2017-02-01 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
US8912324B2
(en)
|
2010-09-01 |
2014-12-16 |
Ambit Biosciences Corporation |
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
US8859502B2
(en)
|
2010-09-13 |
2014-10-14 |
Celgene Corporation |
Therapy for MLL-rearranged leukemia
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
US20120088769A1
(en)
|
2010-10-11 |
2012-04-12 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
|
EP2691384B1
(en)
|
2011-03-28 |
2016-10-26 |
MEI Pharma, Inc. |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
|
US20140088103A1
(en)
|
2011-03-28 |
2014-03-27 |
Mei Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
AU2012236722A1
(en)
|
2011-03-28 |
2013-10-17 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
MX362974B
(es)
|
2011-04-21 |
2019-02-28 |
Curemark Llc |
Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
|
|
EP2723735A4
(en)
|
2011-06-23 |
2015-02-18 |
Map Pharmaceuticals Inc |
NOVEL ANALOGUES OF FLUORO-ERGOLINE
|
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
|
UA124240U
(uk)
|
2011-09-02 |
2018-03-26 |
Общєство С Огранічєной Отвєтствєностью "Новамєдіка" |
Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
CN104114182A
(zh)
|
2011-09-23 |
2014-10-22 |
细胞基因公司 |
罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用
|
|
CN104039330A
(zh)
|
2011-09-26 |
2014-09-10 |
细胞基因公司 |
化疗耐药性的癌症的联合治疗
|
|
TW201700103A
(zh)
|
2011-11-01 |
2017-01-01 |
西建公司 |
利用胞嘧啶核苷類似物之口服配方治療癌症的方法
|
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
|
AU2012355982A1
(en)
|
2011-12-19 |
2014-07-10 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
US8946420B2
(en)
|
2011-12-21 |
2015-02-03 |
Map Pharmaceuticals, Inc. |
Neuromodulatory compounds
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
IN2012DE00661A
(enExample)
|
2012-03-07 |
2015-08-21 |
Univ Delhi |
|
|
TW201341367A
(zh)
|
2012-03-16 |
2013-10-16 |
Axikin Pharmaceuticals Inc |
３，５－二胺基吡唑激酶抑制劑
|
|
WO2013148919A1
(en)
|
2012-03-30 |
2013-10-03 |
The Regents Of The University Of Colorado, A Body Corporate |
Treatment of multiple myeloma
|
|
SI2844637T1
(en)
|
2012-05-02 |
2018-07-31 |
Boehringer Ingelheim International Gmbh |
Substituted 3-haloallylamine inhibitors of ssao and uses thereof
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
US9732038B2
(en)
|
2012-06-14 |
2017-08-15 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of STAT3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US8551535B1
(en)
|
2012-08-06 |
2013-10-08 |
Sarah McCann |
Homeopathic remedies and methods for enhancing weight loss
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
AU2013202506B2
(en)
|
2012-09-07 |
2015-06-18 |
Celgene Corporation |
Resistance biomarkers for hdac inhibitors
|
|
US9156799B2
(en)
|
2012-09-07 |
2015-10-13 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
US20150272924A1
(en)
|
2012-11-08 |
2015-10-01 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
AU2013202507B9
(en)
|
2012-11-14 |
2015-08-13 |
Celgene Corporation |
Inhibition of drug resistant cancer cells
|
|
AU2013352106B2
(en)
|
2012-11-30 |
2018-04-26 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
|
CA2895829A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
CA2902232C
(en)
|
2013-02-22 |
2020-12-29 |
University Of Southern California |
Methods for treatment of ophthalmic diseases and disorders
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
SMT201800538T1
(it)
|
2013-03-15 |
2019-01-11 |
Univ California |
Diesteri di fosfonato nucleosidico aciclico
|
|
AU2014233185B2
(en)
|
2013-03-15 |
2018-03-15 |
University Of Southern California |
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
|
|
WO2014160698A1
(en)
|
2013-03-26 |
2014-10-02 |
Celgene Corporation |
SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
WO2015090235A1
(en)
|
2013-12-20 |
2015-06-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted piperazine compounds and methods of use thereof
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
TWI705967B
(zh)
|
2014-03-20 |
2020-10-01 |
美商卡佩拉醫療公司 |
苯并咪唑衍生物及其醫藥組合物及使用方法
|
|
CA3175724C
(en)
|
2014-03-20 |
2024-01-09 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
|
|
JP6517319B2
(ja)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ |
置換されたヘテロアリール化合物および使用方法
|
|
EP3142649B1
(en)
|
2014-05-12 |
2019-07-24 |
Conatus Pharmaceuticals, Inc. |
Treatment of the complications of chronic liver disease with caspase inhibitor emricasan
|
|
US20150359810A1
(en)
|
2014-06-17 |
2015-12-17 |
Celgene Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
|
WO2015195786A2
(en)
|
2014-06-17 |
2015-12-23 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
US20160045609A1
(en)
|
2014-08-14 |
2016-02-18 |
Mamoun M. Alhamadsheh |
Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
|
|
HRP20220651T1
(hr)
|
2014-09-15 |
2022-08-19 |
The Regents Of The University Of California |
Nukleotidni analozi
|
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
WO2016070107A1
(en)
|
2014-10-31 |
2016-05-06 |
The General Hospital Corporation |
Potent gamma-secretase modulators
|
|
WO2016094837A2
(en)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
|
HUE049801T2
(hu)
|
2014-12-23 |
2020-10-28 |
Sma Therapeutics Inc |
3,5-diaminopirazol kináz inhibitorok
|
|
BR112017015510A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
|
|
CN113149982A
(zh)
|
2015-01-20 |
2021-07-23 |
Xoc制药股份有限公司 |
麦角灵化合物及其用途
|
|
KR102740384B1
(ko)
|
2015-03-03 |
2024-12-06 |
키맵 리미티드 |
항체, 용도 및 방법
|
|
JP2018508593A
(ja)
|
2015-03-20 |
2018-03-29 |
シンダックス ファーマシューティカルズ，インコーポレイティド |
がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
|
|
EP3289104B1
(en)
|
2015-04-29 |
2020-11-04 |
New York University |
Method for treating high-grade gliomas
|
|
WO2016210180A2
(en)
|
2015-06-23 |
2016-12-29 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
EA201890512A1
(ru)
|
2015-08-17 |
2018-09-28 |
Кура Онколоджи, Инк. |
Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
|
|
WO2017041043A1
(en)
|
2015-09-02 |
2017-03-09 |
Syndax Pharmaceuticals, Inc. |
Selection of patients for combination therapy
|
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
|
US10377782B2
(en)
|
2015-09-15 |
2019-08-13 |
The Regents Of The University Of California |
Nucleotide analogs
|
|
WO2017050803A1
(en)
|
2015-09-25 |
2017-03-30 |
Universität Duisburg-Essen |
Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease
|
|
IL284874B2
(en)
|
2015-10-30 |
2023-10-01 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
EP4455145A3
(en)
|
2015-12-02 |
2025-03-12 |
Astraea Therapeutics, LLC |
Piperidinyl nociceptin receptor compounds
|
|
LT3394057T
(lt)
|
2015-12-23 |
2022-06-27 |
Neurocrine Biosciences, Inc. |
Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
|
|
EP3397251A1
(en)
|
2015-12-31 |
2018-11-07 |
Conatus Pharmaceuticals, Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
EP3399978B1
(en)
|
2016-01-08 |
2020-09-09 |
Celgene Corporation |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
US10064855B2
(en)
|
2016-03-08 |
2018-09-04 |
Los Gatos Pharmaceuticals, Inc. |
Composite nanoparticles and uses thereof
|
|
WO2017156183A1
(en)
|
2016-03-08 |
2017-09-14 |
Los Gatos Pharmaceuticals, Inc. |
Camptothecin derivatives and uses thereof
|
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
EP4190357A1
(en)
|
2016-05-13 |
2023-06-07 |
Institut Pasteur |
Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
WO2018013693A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
|
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
MX390121B
(es)
|
2016-09-19 |
2025-03-20 |
Mei Pharma Inc |
Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
|
|
RS61745B1
(sr)
|
2016-11-03 |
2021-05-31 |
Kura Oncology Inc |
Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
WO2018089427A1
(en)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
|
WO2018102252A1
(en)
|
2016-11-30 |
2018-06-07 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
JP7105774B2
(ja)
|
2016-12-01 |
2022-07-25 |
イグナイタ インコーポレイテッド |
がん治療のための方法
|
|
TW202345829A
(zh)
|
2016-12-02 |
2023-12-01 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
KR20230169457A
(ko)
|
2017-01-27 |
2023-12-15 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
AU2018216185B2
(en)
|
2017-02-02 |
2023-08-03 |
Mcmaster University |
Bicarbonate as a potentiator for antimicrobial agents
|
|
CN116730920A
(zh)
|
2017-02-17 |
2023-09-12 |
文涵治疗有限公司 |
Ag-10的制备方法、其中间体及其盐
|
|
KR102003179B1
(ko)
|
2017-02-21 |
2019-07-23 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
BR112019020464A2
(pt)
|
2017-03-30 |
2020-04-28 |
Xw Laboratories Inc. |
compostos derivados de heteroarila bicíclica, composição farmacêutica compreendendo os ditos compostos, adesivo transdérmico compreendendo a dita composição e uso terapêutico dos compostos e composição
|
|
AU2018250823A1
(en)
|
2017-04-10 |
2019-10-17 |
Curemark, Llc |
Compositions for treating addiction
|
|
WO2018195727A1
(en)
|
2017-04-24 |
2018-11-01 |
Tsinghua University |
Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
|
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
JP2020522504A
(ja)
|
2017-06-01 |
2020-07-30 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
多環式化合物およびそれらの用途
|
|
WO2019002228A1
(en)
|
2017-06-26 |
2019-01-03 |
Institut Pasteur |
TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
MX2020001207A
(es)
|
2017-08-07 |
2020-03-20 |
Kura Oncology Inc |
Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
|
|
EP3668837B1
(en)
|
2017-08-17 |
2022-07-06 |
XWPharma Ltd. |
Preparation and uses of reactive oxygen species scavenger derivatives
|
|
ES2953032T3
(es)
|
2017-09-01 |
2023-11-07 |
Univ East Carolina |
Métodos ex vivo para la activación de las células inmunológicas
|
|
EP3988561B1
(en)
|
2017-09-04 |
2023-06-07 |
XWPharma Ltd. |
Preparation and use of reactive oxygen species scavenger
|
|
RS66714B1
(sr)
|
2017-09-21 |
2025-05-30 |
Neurocrine Biosciences Inc |
Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
|
|
CA3076920A1
(en)
|
2017-10-04 |
2019-04-11 |
The Regents Of The University Of California |
Immunomodulatory oligosaccharides
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
MX2020003421A
(es)
|
2017-10-10 |
2020-07-20 |
Neurocrine Biosciences Inc |
Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
|
|
WO2019099353A1
(en)
|
2017-11-15 |
2019-05-23 |
California State University Northridge |
Compositions and methods for the treatment and prevention of cancer
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
KR20260028033A
(ko)
|
2018-01-10 |
2026-03-03 |
엑스더블유파마 리미티드 |
케타민의 전구약물, 및 이의 조성물 및 용도
|
|
AU2019207491A1
(en)
|
2018-01-10 |
2020-07-30 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
|
KR20200130287A
(ko)
|
2018-02-08 |
2020-11-18 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
헤테로아릴 화합물, 이의 약학 조성물 및 이의 치료적 용도
|
|
MA52137A
(fr)
|
2018-03-23 |
2021-01-27 |
Eidos Therapeutics Inc |
Méthodes de traitement de l'amylose ttr à l'aide d'ag10
|
|
CN112423747A
(zh)
|
2018-04-27 |
2021-02-26 |
云杉生物科学公司 |
用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
|
|
AU2019266231B2
(en)
|
2018-05-07 |
2025-08-21 |
Syndax Pharmaceuticals, Inc. |
Selection of patients for combination therapy
|
|
WO2019232724A1
(en)
|
2018-06-06 |
2019-12-12 |
Xw Laboratories, Inc. |
Compounds as nuclear transport modulators and uses thereof
|
|
EP3806856A1
(en)
|
2018-06-14 |
2021-04-21 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
|
EP3814327A1
(en)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
IL280199B2
(en)
|
2018-07-20 |
2025-08-01 |
Pf Medicament |
Receptor for vista
|
|
WO2020019247A1
(en)
|
2018-07-26 |
2020-01-30 |
Xw Laboratories, Inc. |
Compounds as neurokinin-1 receptor antagonists and uses thereof
|
|
EP3829640A4
(en)
|
2018-08-01 |
2022-05-25 |
McMaster University |
Methods for inhibiting microbe growth
|
|
MA53239A
(fr)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
|
AU2019321583C1
(en)
|
2018-08-17 |
2025-11-27 |
Eidos Therapeutics, Inc. |
Formulations of AG10
|
|
EP3856719B1
(en)
|
2018-09-30 |
2023-06-07 |
XWPharma Ltd. |
Compounds as neuronal histamine receptor-3 antagonists and uses thereof
|
|
EP3873469A2
(en)
|
2018-11-01 |
2021-09-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
EP3898609A1
(en)
|
2018-12-19 |
2021-10-27 |
Shy Therapeutics LLC |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
|
US20220071941A1
(en)
|
2018-12-21 |
2022-03-10 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020181165A1
(en)
|
2019-03-07 |
2020-09-10 |
Conatus Pharmaceuticals Inc. |
Caspase inhibitors and methods of use thereof
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
KR20220003554A
(ko)
|
2019-04-19 |
2022-01-10 |
리간드 파마슈티칼스 인코포레이티드 |
화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
|
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
JP7754724B2
(ja)
|
2019-05-20 |
2025-10-15 |
ニルバナ サイエンシーズ インク． |
発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
|
|
CN114222802B
(zh)
|
2019-05-20 |
2025-07-11 |
尼尔瓦纳科学股份有限公司 |
窄发射染料、包含其的组合物以及制备和使用其的方法
|
|
SG11202113211PA
(en)
|
2019-06-03 |
2021-12-30 |
Biotheryx Inc |
Non-hygroscopic crystalline salts of a pyrazole compound, and pharmaceutical compositions and use thereof
|
|
AU2020310190A1
(en)
|
2019-07-11 |
2022-02-24 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
|
EP4003314B1
(en)
|
2019-07-26 |
2024-07-10 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
JP7566889B2
(ja)
|
2019-09-16 |
2024-10-15 |
ダイス・アルファ・インコーポレイテッド |
Ｉｌ－１７ａモジュレーターおよびその使用
|
|
EP4034236A1
(en)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Compounds useful for treating liver diseases
|
|
US12226446B2
(en)
|
2019-10-11 |
2025-02-18 |
Waterstone Pharmaceuticals(Wuhan) Co., Ltd. |
WS-635 uses thereof in medicine
|
|
WO2021092264A1
(en)
|
2019-11-05 |
2021-05-14 |
Dermira, Inc. |
MrgprX2 ANTAGONISTS AND USES THEREOF
|
|
CA3159766A1
(en)
|
2019-11-05 |
2021-05-14 |
Dermira, Inc. |
Mrgprx2 antagonists for the treatment of inflammatory disorders
|
|
CA3159628A1
(en)
|
2019-11-05 |
2021-05-14 |
Dermira, Inc. |
Mrgprx2 antagonists and uses thereof
|
|
CN112851622B
(zh)
|
2019-11-28 |
2023-01-10 |
中国海洋大学 |
一种大环内酯布雷菲德菌素a酯类衍生物及应用
|
|
TW202136237A
(zh)
|
2020-01-06 |
2021-10-01 |
大陸商廣東東陽光藥業有限公司 |
RORγt抑制劑及其製備方法和用途
|
|
TW202136238A
(zh)
|
2020-01-06 |
2021-10-01 |
大陸商廣東東陽光藥業有限公司 |
RORγt抑制劑及其製備方法和用途
|
|
EP4157271A1
(en)
|
2020-05-29 |
2023-04-05 |
Boulder Bioscience LLC |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2021262992A1
(en)
|
2020-06-24 |
2021-12-30 |
Neurobo Pharmaceuticals, Inc. |
Gemcabene for treatment of cytokine storms and viral-induced inflammation
|
|
WO2022002011A1
(zh)
|
2020-06-30 |
2022-01-06 |
东莞市东阳光新药研发有限公司 |
2-(取代的嘧啶基)噻唑甲酰胺化合物的盐及其组合物和用途
|
|
EP4149471A4
(en)
|
2020-06-30 |
2024-07-10 |
Prosetta Biosciences, Inc. |
ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF
|
|
WO2022007769A1
(zh)
|
2020-07-07 |
2022-01-13 |
东莞市东阳光新药研发有限公司 |
吡咯烷酰胺衍生物的盐及其用途
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
WO2022061348A1
(en)
|
2020-09-16 |
2022-03-24 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
TW202231269A
(zh)
|
2020-10-23 |
2022-08-16 |
美商拜歐斯瑞克斯公司 |
Kras蛋白降解劑、其醫藥組合物及其治療應用
|
|
AU2021402911A1
(en)
|
2020-12-14 |
2023-07-06 |
Biotheryx, Inc. |
Pde4 degraders, pharmaceutical compositions, and therapeutic applications
|
|
EP4262770A1
(en)
|
2020-12-16 |
2023-10-25 |
Impact Biomedicines, Inc. |
Dosing of fedratinib
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
IL305752A
(en)
|
2021-03-10 |
2023-11-01 |
Dice Molecules Sv Inc |
INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
|
|
CA3214087A1
(en)
|
2021-04-09 |
2022-10-13 |
Faming Zhang |
Ws635 uses thereof in medicine
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
WO2022266249A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
JP2024522768A
(ja)
|
2021-06-16 |
2024-06-21 |
バイオセリックス， インコーポレイテッド |
Ｓｏｓ１タンパク質分解剤、その医薬組成物及びそれらの治療的応用
|
|
US20240358722A1
(en)
|
2021-09-14 |
2024-10-31 |
Impact Biomedicines, Inc. |
Methods of administering fedratinib
|
|
AU2022368836A1
(en)
|
2021-10-22 |
2024-05-02 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
MX2024005822A
(es)
|
2021-11-30 |
2024-05-28 |
Kura Oncology Inc |
Compuestos macrociclicos con actividad inhibidora de la farnesiltransferasa.
|
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
JP2025501308A
(ja)
|
2022-01-03 |
2025-01-17 |
ライラック セラピューティクス， インク． |
非環式チオールプロドラッグ
|
|
JP2025507621A
(ja)
|
2022-03-02 |
2025-03-21 |
ミトパワー， インク． |
ニコチン酸及びリボースから誘導体化した新規プロドラッグ
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
AR129053A1
(es)
|
2022-04-14 |
2024-07-10 |
Bristol Myers Squibb Co |
Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
|
|
IL316794A
(en)
|
2022-05-10 |
2025-01-01 |
Biotheryx Inc |
CDK protease inhibitors, pharmaceuticals and therapeutic applications
|
|
JP2025526212A
(ja)
|
2022-07-21 |
2025-08-13 |
アンティバ バイオサイエンシズ インコーポレイテッド |
Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形
|
|
JP2025531869A
(ja)
|
2022-09-09 |
2025-09-25 |
イノヴォ セラピューティクス、インコーポレイテッド |
ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
|
|
EP4593826A1
(en)
|
2022-09-30 |
2025-08-06 |
Boulder Bioscience LLC |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
EP4608838A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
EP4626864A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
AU2024316921A1
(en)
|
2023-07-28 |
2026-02-05 |
Sunshine Lake Pharma Co., Ltd. |
Substituted nitrogen-containing bicyclic compound and use thereof
|
|
AU2024344247A1
(en)
|
2023-09-19 |
2026-05-07 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
IL327069A
(en)
|
2023-09-27 |
2026-05-01 |
Isosterix Inc |
Mist inhibitors
|
|
WO2025072489A2
(en)
|
2023-09-27 |
2025-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025201633A1
(en)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
An agent for reducing amyloid formation
|
|
WO2025231261A1
(en)
|
2024-05-01 |
2025-11-06 |
Protego Biopharma, Inc. |
Bicyclic and heterocyclic amide compounds
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|